Castleark Management’s DexCom DXCM Stock Holding History

Castleark Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-300,249	Closed	-$20.2M	–	308
2025 Q3	$20.2M	Sell	300,249 -11,093	-4%	-$878K	0.57%	30
2025 Q2	$27.2M	Buy	+311,342	New	+$24.4M	0.82%	27
2024 Q3	–	Sell	-438,078	Closed	-$49.7M	–	284
2024 Q2	$49.7M	Buy	438,078 +5,680	+1%	+$718K	2.03%	13
2024 Q1	$60M	Sell	432,398 -5,749	-1%	-$723K	2.49%	10
2023 Q4	$54.4M	Sell	438,147 -12,903	-3%	-$1.32M	2.41%	9
2023 Q3	$42.1M	Sell	451,050 -2,230	-0.5%	-$251K	2.14%	12
2023 Q2	$58.3M	Buy	453,280 +1,130	+0.2%	+$137K	2.64%	7
2023 Q1	$52.5M	Buy	452,150 +50,520	+13%	+$5.66M	2.58%	9
2022 Q4	$45.5M	Buy	401,630 +264,590	+193%	+$29M	2.38%	9
2022 Q3	$11M	Sell	137,040 -54,700	-29%	-$4.63M	0.61%	32
2022 Q2	$14.3M	Sell	191,740 -51,200	-21%	-$4.67M	0.76%	28
2022 Q1	$31.1M	Buy	242,940 +4,880	+2%	+$534K	1.34%	18
2021 Q4	$32M	Buy	238,060 +1,880	+0.8%	+$270K	1.17%	19
2021 Q3	$32.3M	Buy	236,180 +3,860	+2%	+$487K	1.23%	22
2021 Q2	$24.8M	Sell	232,320 -2,080	-0.9%	-$200K	0.83%	31
2021 Q1	$21.1M	Sell	234,400 -6,260	-3%	-$588K	0.76%	32
2020 Q4	$22.2M	Sell	240,660 -6,180	-3%	-$552K	0.83%	30
2020 Q3	$25.4M	Sell	246,840 -38,300	-13%	-$4M	1%	28
2020 Q2	$28.9M	Sell	285,140 -146,340	-34%	-$13.1M	1.26%	19
2020 Q1	$29M	Buy	431,480 +281,640	+188%	+$17.5M	1.72%	10
2019 Q4	$8.19M	Sell	149,840 -227,520	-60%	-$10.8M	0.33%	103
2019 Q3	$14.1M	Sell	377,360 -24,268	-6%	-$943K	0.57%	40
2019 Q2	$15M	Sell	401,628 -92,540	-19%	-$2.91M	0.58%	36
2019 Q1	$14.7M	Sell	494,168 -190,264	-28%	-$6.69M	0.55%	43
2018 Q4	$20.5M	Sell	684,432 -171,380	-20%	-$5.44M	0.87%	27
2018 Q3	$30.6M	Buy	855,812 +267,608	+45%	+$8.3M	0.88%	24
2018 Q2	$14M	Buy	+588,204	New	+$12.5M	0.43%	72
2017 Q2	–	Sell	-153,380	Closed	-$3.25M	–	403
2017 Q1	$3.25M	Buy	+153,380	New	+$2.99M	0.1%	231
2016 Q1	–	Sell	-170,040	Closed	-$3.48M	–	379
2015 Q4	$3.48M	Buy	170,040 +24,320	+17%	+$506K	0.1%	215
2015 Q3	$3.13M	Buy	+145,720	New	+$3.25M	0.1%	225
2014 Q4	–	Sell	-821,480	Closed	-$8.49M	–	354
2014 Q3	$8.49M	Buy	+821,480	New	+$8.4M	0.24%	92
2014 Q2	–	Sell	-821,480	Closed	-$8.49M	–	321
2014 Q1	$8.49M	Sell	821,480 -472,248	-37%	-$4.88M	0.24%	92
2013 Q4	$11.5M	Buy	+1,293,728	New	+$10.2M	0.33%	52
2013 Q3	–	Sell	-1,244,300	Closed	-$6.98M	–	359
2013 Q2	$6.98M	Buy	+1,244,300	New	+$5.96M	0.23%	51

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Castleark Management's DXCM Position: Q4 2025 in Review

Castleark Management sold out of DexCom (DXCM) in Q4 2025, closing a stake of 300,249 shares — an estimated $20.2M sold.

Castleark Management first reported a position in DXCM in Q2 2013 and held it in 34 quarters. The position peaked at $60M in Q1 2024. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Castleark Management reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Castleark Management sold 300,249 DexCom shares in Q4 2025, an estimated $20.2M.
Castleark Management first reported a position in DexCom in Q2 2013 and held it in 34 quarters.
Castleark Management's DexCom position peaked at $60M in Q1 2024.
920 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Castleark Management's 13F filing for Q4 2025, filed 13 Feb 2026.